Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
Author:
Affiliation:
1. Research and Development Department, Akeso Biopharma, Inc, Zhongshan, China
Funder
any specific grant from funding agencies in the public, commercial, or not-for-profit sectors
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/19420862.2023.2180794
Reference30 articles.
1. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
2. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer
3. Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
4. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
5. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody;Immunobiology;2024-11
2. Advancements in a novel model of autophagy and immune network regulation in radioresistance of cancer stem cells;Biomedicine & Pharmacotherapy;2024-10
3. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11
4. Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges;Molecular Biotechnology;2024-09-02
5. Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B;Antiviral Research;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3